Long-term persistence of immunity and B-cell memory following Haemophilus influenzae type b conjugate vaccination in early childhood and response to booster

Clinical Infectious Diseases

Volumn 58, Issue 7, 2014, Pages 949-959

  Perrett, K P ^a,b   John, T M ^a   Jin, C ^a   Kibwana, E ^a   Yu, L M ^a   Curtis, N ^b   Pollard, A J ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

B cell memory; Booster vaccination; Childhood immunization; Haemophilus influenzae type b; Long term persistence of immunity

Indexed keywords

ANTIBODY; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; IMMUNOGLOBULIN G; MENINGOCOCCUS VACCINE; HAEMOPHILUS VACCINE;

ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ARTICLE; CELL SPECIFICITY; CELLULAR IMMUNITY; CHILD; EARLY CHILDHOOD INTERVENTION; GROUPS BY AGE; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNOLOGICAL MEMORY; INFANT; MEMORY CELL; NORMAL HUMAN; OPEN STUDY; PHASE 4 CLINICAL TRIAL; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT RESPONSE; VACCINATION; B LYMPHOCYTE; BLOOD; CLINICAL TRIAL; FEMALE; HAEMOPHILUS INFECTIONS; IMMUNIZATION; IMMUNOLOGY; MALE; TIME;

B-LYMPHOCYTES; CHILD; FEMALE; HAEMOPHILUS INFECTIONS; HAEMOPHILUS VACCINES; HUMANS; IMMUNIZATION, SECONDARY; IMMUNOGLOBULIN G; IMMUNOLOGIC MEMORY; MALE; TIME FACTORS;

EID: 84904996546     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu001     Document Type: Article

References (42)

1. Ramsay ME, et al. Estimating Haemophilus influenzae type b vaccine effectiveness in England and Wales by use of the screening method. J Infect Dis 2003; 188:481-5.
2. Booy R, et al. Efficacy of Haemophilus influenzae type b conjugate vaccine PRP-T. Lancet 1994; 344:362-6.
3. Trotter CL, Ramsay ME, Slack MP. Rising incidence of Haemophilus influenzae type b disease in England and Wales indicates a need for a second catch-up vaccination campaign. Commun Dis Public Health 2003; 6:55-8.
4. Kelly DF, Moxon ER, Pollard AJ. Haemophilus influenzae type b conjugate vaccines. Immunology 2004; 113:163-74.
5. Heath PT, et al. Antibody concentration and clinical protection after Hib conjugate vaccination in the United Kingdom. JAMA 2000; 284:2334-40.
6. Oh SY, et al. School-aged children: a reservoir for continued circulation of Haemophilus influenzae type b in the United Kingdom. J Infect Dis 2008; 197:1275-81.
7. Trotter CL, et al. Antibody to Haemophilus influenzae type b after routine and catch-up vaccination. Lancet 2003; 361:1523-4.
8. McVernon J, et al. Risk of vaccine failure after Haemophilus influenzae type b (Hib) combination vaccines with acellular pertussis. Lancet 2003; 361:1521-3.
9. Kitchin NR, et al. Evaluation of a diphtheria-tetanus-acellular pertussisinactivated poliovirus-Haemophilus influenzae type b vaccine given concurrently with meningococcal group C conjugate vaccine at 2, 3 and 4 months of age. Arch Dis Child 2007; 92:11-6.
10. Heath PT, McVernon J. The UK Hib vaccine experience. Arch Dis Child 2002; 86:396-9.
11. van Alphen L, et al. Effect of nationwide vaccination of 3-month-old infants in the Netherlands with conjugate Haemophilus influenzae type b vaccine: high efficacy and lack of herd immunity. J Pediatr 1997; 131:869-73.
12. Makela PH, et al. Long-term persistence of immunity after immunisation with Haemophilus influenzae type b conjugate vaccine. Vaccine 2003; 22:287-92.
13. UK Department of Health. Planned Hib vaccination catch-up campaign: further information. 2003. Available at: http://www.dh.gov.uk/ en/publicationsandstatistics/lettersandcirculars/professionalletters/ chiefmedicalofficerletters/dh-4004833. Accessed 19 April 2011.
14. Heath PT, Ramsay ME. Haemophilus influenzae type b vaccine - booster campaign. BMJ 2003; 326:1158-9.
15. UK Department of Health. Important changes to the childhood immunisation programme. 2006. Available at: http://www.dh.gov.uk/ en/publicationsandstatistics/lettersandcirculars/professionalletters/ chiefmedicalofficerletters/dh-4137171. Accessed 19 April 2011.
16. Perrett KP, et al. Antibody persistence after serogroup C meningococcal conjugate immunization of United Kingdom primary-school children in 1999-2000 and response to a booster: a phase 4 clinical trial. Clin Infect Dis 2010; 50:1601-10.
17. Pickering JW, et al. Comparison of a multiplex flow cytometric assay with enzyme-linked immunosorbent assay for auantitation of antibodies to tetanus, diphtheria, and Haemophilus influenzae type b. Clin Diagn Lab Immunol 2002; 9:872-6.
18. Perrett KP, et al. B cell memory to a serogroup C meningococcal conjugate vaccine in childhood and response to booster: little association with serum IgG antibody. J Immunol 2012; 189:2673-81.
19. Kayhty H, et al. The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b. J Infect Dis 1983; 147:1100.
20. Anderson P. The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b. J Infect Dis 1984; 149:1034-5.
21. Tejedor JC, et al. Immunogenicity and reactogenicity of a booster dose of a novel combined Haemophilus influenzae type b-Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine given to toddlers of 13-14 months of age with antibody persistence up to 31 months of age. Pediatr Infect Dis J 2008; 27:579-88.
22. Heath PT, et al. Antibody persistence and Haemophilus influenzae type b carriage after infant immunisation with PRP-T. Arch Dis Child 1997; 77:488-92.
23. Southern J, et al. Immunogenicity of a fourth dose of Haemophilus influenzae type b (Hib) conjugate vaccine and antibody persistence in young children from the United Kingdom who were primed with acellular or whole-cell pertussis component-containing Hib combinations in infancy. Clin Vaccine Immunol 2007; 14:1328-33.
24. Nolan T, et al. Antibody persistence, PRP-specific immune memory, and booster responses in infants immunised with a combination DTPa-HBV-IPV/Hib vaccine. Vaccine 2004; 23:14-20.
25. Johnson NG, et al. Haemophilus influenzae type b reemergence after combination immunization. Emerg Infect Dis 2006; 12:937-41.
26. Goldblatt D, et al. Immunological response to conjugate vaccines in infants: follow up study. BMJ 1998; 316:1570-1.
27. Goldblatt D, et al. The induction of immunologic memory after vaccination with Haemophilus influenzae type b conjugate and acellular pertussis-containing diphtheria, tetanus, and pertussis vaccine combination. J Infect Dis 1999; 180:538-41.
28. Granoff DM, et al. Haemophilus influenzae type b in a day care center: relationship of nasopharyngeal carriage to development of anticapsular antibody. Pediatrics 1980; 65:65-8.
29. Hall DB, et al. Pharyngeal carriage and acquisition of anticapsular antibody to Haemophilus influenzae type b in a high-risk population in southwestern Alaska. Am J Epidemiol 1987; 126:1190-7.
30. Schneerson R, Robbins JB. Induction of serum Haemophilus influenzae type B capsular antibodies in adult volunteers fed cross-reacting Escherichia coli 075:K100:H5. N Engl J Med 1975; 292:1093-6.
31. Myerowitz RL, et al. Induction of Haemophilus influenzae type b capsular antibody in neonatal rabbits by gastrointestinal colonization with cross-reacting Escherichia coli. Infect Immun 1973; 7:137-40.
32. Schmitt HJ, et al. Immunogenicity, reactogenicity, and immune memory after primary vaccination with a novel Haemophilus influenzae-Neisseria meningitidis serogroup C conjugate vaccine. Clin Vaccine Immunol 2007; 14:426-34.
33. Tejedor JC, et al. Immunogenicity and reactogenicity of primary immunization with a hexavalent diphtheria-tetanus-acellular pertussishepatitis B-inactivated polio-Haemophilus influenzae type B vaccine coadministered with two doses of a meningococcal C-tetanus toxoid conjugate vaccine. Pediatr Infect Dis J 2006; 25:713-20.
34. Khatami A, et al. Persistence of immunity following a booster dose of Haemophilus influenzae type B-meningococcal serogroup C glycoconjugate vaccine: follow-up of a randomized controlled trial. Pediatr Infect Dis J 2011; 30:97-202.
35. Tapsall J. Annual report of the Australian Meningococcal Surveillance Programme, 2008. Commun Dis Intell Q Rep 2009; 33:259-67.
36. Blanchard Rohner G, et al. The magnitude of the antibody and memory B cell responses during priming with a protein-polysaccharide conjugate vaccine in human infants is associated with the persistence of antibody and the intensity of booster response. J Immunol 2008; 180:2165-73.
37. Slifka MK, Matloubian M, Ahmed R. Bone marrow is a major site of long-term antibody production after acute viral infection. J Virol 1995; 69:1895-902.
38. Manz RA, Thiel A, Radbruch A. Lifetime of plasma cells in the bone marrow. Nature 1997; 388:133-4.
39. Richmond P, et al. Meningococcal serogroup C conjugate vaccine is immunogenic in infancy and primes for memory. J Infect Dis 1999; 179:1569-72.
40. Danilova E, et al. Attenuated immune response to tetanus toxoid in young healthy men protected against tetanus. Vaccine 2005; 23:4980-3.
41. Nanan R, et al. Acute and long-term effects of booster immunisation on frequencies of antigen-specific memory B-lymphocytes. Vaccine 2001; 20:498-504.
42. Health Protection Agency, United Kingdom. Laboratory reports of Haemophilus influenzae type b infection by age group and quarter: England and Wales: 1990-2009. Available at: http://www.hpa.org.uk/ Topics/InfectiousDiseases/InfectionsAZ/HaemophilusInfluenzaeTypeB/ EpidemiologicalData/haem-DataLabAgeQtr/. Accessed 30 March 2011.